ALKS|Alkermes Plc|Price:38.600|Chg%:0.31

More Details of Alkermes Plc Company

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Alkermes Plc Info



Ticker SymbolALKS

Company nameAlkermes Plc

IPO dateJul 16, 1991

CEOPops (Richard F)

Number of employees1800

Security typeOrdinary Share

Fiscal year-endJul 16

AddressConnaught House

CityDUBLIN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryIreland

Postal codeD04 C5Y6

Phone35317728000

Websitehttps://www.alkermes.com/

Ticker SymbolALKS

IPO dateJul 16, 1991

CEOPops (Richard F)

Company Executives of Alkermes Plc



Name

Name/Position

Position

Shareholding

Change

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.38M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

231.56K

-0.88%

Mr. Shane M. Cooke

Independent Director

103.74K

--

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

81.39K

-4.91%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

--

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

--

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

--

Ms. Nancy S. Lurker

Independent Director

13.55K

+21.03%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

Mr. C. Todd Nichols

Senior Vice President, Chief Commercial Officer

--

Name

Name/Position

Position

Shareholding

Change

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.38M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

231.56K

-0.88%

Mr. Shane M. Cooke

Independent Director

103.74K

--

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

81.39K

-4.91%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

--

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

--

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

VIVITROL

467.91M

31.70%

ARISTADA

370.04M

25.07%

LYBALVI

346.69M

23.49%

Royalty Revenue - VUMERITY

113.93M

7.72%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

109.57M

7.42%

Other

67.75M

4.59%

By RegionUSD

Name

Revenue

Proportion

United States

1.37B

93.01%

Rest of the World

102.36M

6.94%

Ireland

754.00K

0.05%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

VIVITROL

467.91M

31.70%

ARISTADA

370.04M

25.07%

LYBALVI

346.69M

23.49%

Royalty Revenue - VUMERITY

113.93M

7.72%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

109.57M

7.42%

Other

67.75M

4.59%

Shareholding Stats

Updated: Thu, May 7

Shareholders

Shareholder Types

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

14.44%

Baker Bros. Advisors LP

6.01%

Vanguard Portfolio Management, LLC

5.71%

State Street Investment Management (US)

5.68%

T. Rowe Price Associates, Inc.

5.28%

Other

62.88%

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

14.44%

Baker Bros. Advisors LP

6.01%

Vanguard Portfolio Management, LLC

5.71%

State Street Investment Management (US)

5.68%

T. Rowe Price Associates, Inc.

5.28%

Other

62.88%

Shareholder Types

Shareholders

Proportion

Investment Advisor

53.52%

Investment Advisor/Hedge Fund

29.75%

Hedge Fund

19.22%

Research Firm

2.49%

Pension Fund

2.14%

Individual Investor

1.41%

Sovereign Wealth Fund

1.17%

Bank and Trust

0.48%

Private Equity

0.42%

Institutional Shareholding



Updated: Wed, Apr 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

783

182.39M

109.43%

-12.00M

2025Q4

744

175.23M

117.54%

-23.12K

2025Q3

767

175.30M

122.16%

+2.11M

2025Q2

769

173.38M

125.62%

-4.15M

2025Q1

759

177.46M

124.05%

-27.05M

2024Q4

734

172.08M

130.58%

-12.03M

2024Q3

705

184.36M

134.23%

-884.11K

2024Q2

687

185.17M

126.42%

+3.87M

2024Q1

659

181.61M

124.10%

-28.36M

2023Q4

633

182.01M

111.83%

+12.84M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Institutional Trust Company, N.A.

24.07M

14.44%

+417.41K

+1.76%

Dec 31, 2025

Baker Bros. Advisors LP

10.01M

6.01%

+1.92M

+23.74%

Dec 31, 2025

State Street Investment Management (US)

9.47M

5.68%

+932.51K

+10.92%

Dec 31, 2025

T. Rowe Price Associates, Inc.

8.80M

5.28%

-1.25M

-12.41%

Dec 31, 2025

Renaissance Technologies LLC

6.67M

4%

+375.50K

+5.97%

Dec 31, 2025

American Century Investment Management, Inc.

5.96M

3.57%

+1.56M

+35.46%

Dec 31, 2025

JP Morgan Asset Management

4.83M

2.9%

+1.21M

+33.37%

Dec 31, 2025

Dimensional Fund Advisors, L.P.

4.41M

2.65%

+714.79K

+19.33%

Dec 31, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

AdvisorShares Psychedelics ETF

7.31%

iShares Neuroscience and Healthcare ETF

3.82%

First Trust NYSE Arca Biotechnology Index Fund

3.3%

Invesco S&P SmallCap Health Care ETF

3.1%

ALPS Medical Breakthroughs ETF

2.07%

Knowledge Leaders Developed World ETF

1.69%

Langar Global HealthTech ETF

1.44%

State Street SPDR S&P Biotech ETF

1.35%

Abacus FCF International Leaders ETF

1.34%

Invesco S&P SmallCap Quality ETF

1.32%

AdvisorShares Psychedelics ETF

Proportion7.31%

iShares Neuroscience and Healthcare ETF

Proportion3.82%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.3%

Invesco S&P SmallCap Health Care ETF

Proportion3.1%

ALPS Medical Breakthroughs ETF

Proportion2.07%

Knowledge Leaders Developed World ETF

Proportion1.69%

Langar Global HealthTech ETF

Proportion1.44%

State Street SPDR S&P Biotech ETF

Proportion1.35%

Abacus FCF International Leaders ETF

Proportion1.34%

Invesco S&P SmallCap Quality ETF

Proportion1.32%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data